 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || INV-1120 / Ionova Life Sci
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: INV-1120-101: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 17, 2024
P1, N=78, Recruiting, Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
- INV-1120 / Ionova Life Sci
Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4618;
P1a/1b
Data from this trial were in line with data in a Western population [NCT04443088, presented @ SITC 2022] and warrant further Global development. Due to the combined findings of this study and the above-mentioned sister study, the doses of 60, 100 and/or 150mg QD are proposed for further exploration in combination trials.Clinical trial information: ChiCTR20211872.
- INV-1120 / Ionova Life Sci
Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_924;
P1a/1b
Trial Registration Clinical trial registry number: NCT04443088 . Ethics statement: This study was approved by IntegReview IRB.
- || INV-1120 / Ionova Life Sci
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: INV-1120-101: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 23, 2022
P1a/1b, N=78, Recruiting, Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Ethics statement: This study was approved by IntegReview IRB. Phase classification: P1 --> P1a/1b | N=28 --> 78 | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
- | INV-1120 / Ionova Life Sci
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INV-1120-101: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 12, 2021
P1, N=28, Recruiting, Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Phase classification: P1 --> P1a/1b | N=28 --> 78 | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023 Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- || INV-1120 / Ionova Life Sci
Enrollment open, Combination therapy, Metastases: INV-1120-101: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 6, 2020
P1, N=28, Recruiting, Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting
- | INV-1120 / Ionova Life Sci
New P1 trial, Combination therapy, Metastases: INV-1120-101: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 22, 2020
P1, N=28, Not yet recruiting, Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.